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Abstract
Background: Preeclampsia is a serious pregnancy complication, demonstrating a complex pattern of inheritance. The
elucidation of genetic liability to preeclampsia remains a major challenge in obstetric medicine. We have adopted a
positional cloning approach to identify maternal genetic components, with linkages previously demonstrated to
chromosomes 2q, 5q and 13q in an Australian/New Zealand familial cohort. The current study aimed to identify potential
functional and structural variants in the positional candidate gene TNFSF13B under the 13q linkage peak and assess their
association status with maternal preeclampsia genetic susceptibility.
Methodology/Principal Findings: The proximal promoter and coding regions of the positional candidate gene TNFSF13B
residing within the 13q linkage region was sequenced using 48 proband or founder individuals from Australian/New
Zealand families. Ten sequence variants (nine SNPs and one single base insertion) were identified and seven SNPs were
successfully genotyped in the total Australian/New Zealand family cohort (74 families/480 individuals). Borderline
association to preeclampsia (p=0.0153) was observed for three rare SNPs (rs16972194, rs16972197 and rs56124946) in
strong linkage disequilibrium with each other. Functional evaluation by electrophoretic mobility shift assays showed
differential nuclear factor binding to the minor allele of the rs16972194 SNP, residing upstream of the translation start site,
making this a putative functional variant. The observed genetic associations were not replicated in a Norwegian case/
control cohort (The Nord-Trøndelag Health Study (HUNT2), 851 preeclamptic and 1,440 non-preeclamptic women).
Conclusion/Significance: TNFSF13B has previously been suggested to contribute to the normal immunological adaption
crucial for a successful pregnancy. Our observations support TNFSF13B as a potential novel preeclampsia susceptibility gene.
We discuss a possible role for TNFSF13B in preeclampsia pathogenesis, and propose the rs16972194 variant as a candidate
for further functional evaluation.
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Introduction
Preeclampsia is a major cause of fetal and maternal morbidity
and mortality in pregnancy, with an incidence ranging from 2–5%
[1]. A complete understanding of the etiology and pathogenesis of
the preeclampsia syndrome remains elusive. The clinical manifes-
tations of hypertension and proteinuria usually emerge after 20
weeks of pregnancy, and are caused by inflammatory changes and
endothelial dysfunction [2,3]. Impaired placentation in the earlier
stages of pregnancy is an underlying pathological feature [4].
However, immunological changes occurring before placentation
[5] and even before implantation [6] are also implied in the
pathogenesis. Therefore a three stage model for preeclampsia is
proposed [7,8] in which immunological dysfunction (stage 1) is
followed by impaired placentation (stage 2), leading to an
enhanced inflammatory state and overt preeclampsia (stage 3).
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12993Maternal-fetal immune maladaption is an intriguing aspect of
preeclampsia pathogenesis, for which there is both epidemiological
and biological evidence [9–14]. Importantly, the theory implies a
mechanism which by partial failure will lead to poor placentation,
but by more severe failure will cause spontaneous abortion.
Indeed, observations of immunological pathogenic factors place
preeclampsia as an intermediate phenotype between miscarriage
and successful pregnancy [8].
Like in the majority of other common complex disorders,
the mode of preeclampsia inheritance is unclear [15–17]. By
examining the probability of co-segregating loci within familial
cohorts, several loci most likely to harbor maternal susceptibility
genes have been identified [18–24]. Genome-wide linkage studies
in our Australian/New Zealand (Aust/NZ) familial cohort initially
identified a maternal preeclampsia susceptibility locus to chromo-
some 2q [23,25]. Re-analysis of the Aust/NZ data set, assuming
an underlying inherent quantitative liability for preeclampsia,
resolved and strengthened the chromosome 2 linkage signal to
2q22 [24]. Two additional novel maternal preeclampsia suscep-
tibility quantitative trait loci (QTLs) on chromosomes 5q and 13q
were revealed [20,24]. An extended Aust/NZ familial cohort and
an independent retrospectively ascertained Norwegian case/
control cohort (the HUNT2 cohort) have been utilized to identify
maternal preeclampsia susceptibility genes at these QTLs.
Association to the activin A receptor, type IIA (ACVR2A) [26,27]
and the endoplasmic reticulum aminopeptidase 2 (ERAP2) [28]
genes at the 2q22 and 5q QTLs, respectively, has been reported.
Priorization of candidate susceptibility genes at the 13q QTL, was
performed using the database text-mining program GeneSniffer
(www.genesniffer.org) [20,24,28], literature searches and interro-
gating publically available SNP loci in the Aust/NZ and
Norwegian cohorts (NCBI SNP database, dbSNP build 125, Sep
2005) [29]. This preliminary assessment identified the tumor
necrosis factor (ligand) superfamily 13B (TNFSF13B) as our most
promising candidate gene [29].
TNFSF13B, also known as BAFF, BLYS, TALL-1, zTNF4,
THANK, CD257, TNFSF20 and DTL, is a member of the TNF
superfamily. This protein is active both as a membrane-bound and
soluble ligand. Originally discovered as an important stimulator of
B-cell proliferation and immunoglobulin production [30,31],
TNFSF13B has later been shown to hold various roles in the
innate immune system [32]. Both malignant [33–35] and
autoimmune [36,37] B-cell diseases have been linked to this
protein. Furthermore, TNFSF13B has been implicated in normal
placental development [38,39], with reduced expression in
recurrent spontaneous miscarriage patients [40].
The current study aimed to identify potential functional and
structural variants in TNFSF13B by re-sequencing the proximal
promoter area and coding regions of the gene in preeclamptic
individuals from our Aust/NZ families. Identified variants were
tested for association with maternal preeclampsia genetic suscep-
tibility in the extended Aust/NZ families. Associated variants were
further assessed by formal molecular genetics analyses followed by
attempts to independently replicate genetic association findings in
a large Norwegian case/control cohort.
Materials and Methods
Ethics
Australia. Ethical approval for the recruitment of Aust/NZ
preeclampsia family members was granted by the Royal Women’s
Hospital Research and Ethics Committees, Melbourne, Australia.
Written informed consent was obtained from study participants
prior to them being phlebotomized. Ethical approval for the
molecular genetic investigation across the 13q QTL in The 74
Family Cohort was obtained from The University of Texas Health
Science Center at San Antonio, Institutional Review Board. Data
were analyzed anonymously.
Norway. Prior approval to link the information in the HUNT
and MBRN databases, to use the Norwegian case/control cohort
for genetic studies, and to export samples was obtained by the
Regional Committee for Medical Research Ethics, Norway and
approved by the National Data Inspectorate and The Directorate
of Health and Social Welfare. Ethical approval for genotyping and
statistical analysis of the Norwegian case/control cohort was also
obtained from The University of Texas Health Science Center at
San Antonio, Institutional Review Board. Data were analyzed
anonymously.
Aust/NZ Study Population
The Aust/NZ familial cohort consists of the original set of 34
(26 Australian and eight New Zealand) families that we have
previously used to localize the 2q, 5q and 13q preeclampsia
susceptibility QTLs and an additional 40 (Australian) preeclamp-
sia families that we have subsequently ascertained and recently
described [26]. The entire familial sample is herein called ‘‘The 74
Family Cohort’’. All family members are of Caucasian origin.
Preeclampsia diagnosis in the Aust/NZ study population was
performed by qualified clinicians, using criteria set by the
Australasian Society for the Study of Hypertension in Pregnancy
(new onset proteinuria, $0.3 g/d and either an increase from
baseline blood pressure of 15/25 mmHg or absolute values $140/
90 mmHg on at least two occasions 6 h or more apart) [41,42] as
described in detail elsewhere [23,26]. Women who met the
preeclamptic criteria of new onset of hypertension and proteinuria
in pregnancy, and experienced convulsions or unconsciousness in
the prenatal period were classified as having had eclampsia.
Women with pre-existing hypertension or other medical condi-
tions known to predispose for preeclampsia (e.g. renal disease,
diabetes, twin pregnancies or fetal chromosomal abnormalities)
were excluded. Family members were coded as 1) affected, 2)
unaffected or 3) unknown (e.g. male, non-fertile women).
Norwegian Study Population
All women in the Norwegian cohort were identified from Nord-
Trøndelag County in Norway as part of a large multipurpose
health survey conducted during 1995–1997 (the Nord-Trøndelag
Health Study, HUNT2) [43]. Preeclamptic women and women
who had non-preeclamptic pregnancies were retrospectively
identified in the HUNT cohort by linking the HUNT database
to the database at the Medical Birth Registry of Norway (MBRN)
as previously described [44,45]. Preeclampsia was defined in
accordance with the National High Blood Pressure Education
Program Working Group on High Blood Pressure in Pregnancy
(new onset hypertension, blood pressure $140/90 mmHg, and
proteinuria, $0.3 g/d in pregnancy) [46] using diagnosis codes
ICD-8 (before 1998) and ICD-10 (after 1998) as previously
described [44,45]. Preeclamptic women with multiple pregnancies
were excluded. Two controls per case were identified at random
among parous women in the HUNT2 cohort with no registered
preeclamptic pregnancy in the MBRN. Information stored in
hospital records was retrospectively examined by an independent
obstetrician for validation of the diagnosis reported to MBRN.
Positional Candidate Gene Sequencing
Two kb of the proximal promoter (upstream of the translation
start site) and all six exons (translated or untranslated) of the 13q
preeclampsia QTL candidate gene, TNFSF13B (NM_006573.3)
TNFSF13B/BAFF and Preeclampsia
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12993were sequenced in 48 preeclamptic women. These women are a
selection of founders or probands chosen from the most
informative pedigrees in The 74 Family Cohort. This sequencing
sample set will give a greater than 99% probability of detecting
any polymorphism that has a frequency of 0.05 or greater.
Primer Design for TNFSF13B Gene Sequencing
Sequence information for use as a reference template was
obtained from the UCSC Genome Browser (Human, Mar. 2006
[NCBI/hg 18]). Sequencing primers were designed using Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast). Prim-
ers were designed to be between 20 and 27 bp in length with an
annealing temperature between 55uC and 63uC and within 1uCo f
each other (Table 1).
TNFSF13B Gene Sequencing
Extraction of genomic DNA from peripheral blood samples has
been previously described [23]. PCR was performed with 20 ng
genomic DNA in a 5 ml reaction containing 0.25 U HotStarTaq
DNA Polymerase (QIAGEN), 16QIAGEN PCR buffer, 0.2 mM
dNTP, and 0.2 mM of each forward and reverse primer (Table 1).
A GeneAmp 9700 thermal cycler (Applied Biosystems) was used
for PCR amplification. After an initial denaturation step at 95uC
for 15 min, 40 cycles of 94uC for 30 s, a primer pair specific
annealing temperature (Table 1) for 30 s, and 72uC for 30 s were
run followed by a final extension step of 72uC for 10 min. PCR
products were purified using ExoSAP-IT (Amersham Biosciences)
according to the manufactures instructions before they were used
as a template for sequencing. Sequencing reactions were
performed independently for both sense and anti-sense DNA
strands using 1 ml purified PCR product in a 5 ml reaction,
containing 0.25 ml AB BigDye Terminators v3.1 (Applied
Biosystems), 16 AB BigDye Terminator v3.1 buffer (Applied
Biosystems) and 1.6 mM of either forward or reverse primer.
Sequence reaction amplification was performed on a GeneAmp
9700 thermal cycler using standard cycling conditions, 96uC for
1 min followed by 25 cycles of 96uC for 10 s, 50uC for 10 s and
then 60uC for 4 min. The Applied Biosystems BigDye XTermi-
nator purification kit was used according to manufacturer’s
instructions to purify all sequenced products. Purified sequence
reactions were electrophoretically separated on an Applied
Biosystems 3730xl DNA Analyzer. Sequence variant identification
was performed using Applied Biosystems’ SeqScape software v2.6.
SNP Genotyping in the Aust/NZ Study Population
All TNFSF13B SNPs identified in our sequencing experiments
were incorporated into a custom Illumina SNP pool and
genotyped back in The 74 Family Cohort. Briefly, SNP designs
were uploaded to Illumina’s Assay Design Tool to design a custom
GoldenGate SNP pool with VeraCode technology (Illumina Inc.,
CA). The design of two allele specific oligos and one locus specific
oligo in conjunction with a universal set of amplification primers
followed by hybridization to complementary VeraCode bead types
makes the GoldenGate assay with VeraCode technology highly
robust and specific in a small to medium multiplex reaction. Each
VeraCode microtitre bead plate was imaged on the Illumina
BeadXpress Reader System using Illumina VeraScan image data
acquisition software (version 1.1.9.2). SNP genotype clustering and
individual sample genotype calls were interrogated using the
Illumina GenomeStudio software, Genotyping Module (version
1.1.9). As an added measure we confirmed genotype calls made by
GenomeStudio against the sequence data obtained from our
sequencing sub-set of The 74 Family Cohort (n=48).
Table 1. Primers used for TNFSF13B PCR amplification and sequencing.
Name Primer Sequence Fragment size (bp) Annealing temperature (uC)
Promoter 1 F AGACGTTACAAGCACAGTTGTAGAA 652 60
Promoter 1 R CCGAGCAGTGTACACATTGAA 60
Promoter 2 F CATAGGAATGATCTAATGGACTTTAG 631 57
Promoter 2 R CATTCTAGTCCTGCCTTATCCT 57
Promoter 3 F TTCTCCACTTTGCACTATATCATTTC 585 58
Promoter 3 R AACATGCATAAACTTTTTCCTTCTG 58
Promoter 4 F TAGTATCATATTGAGCGGGGACTTA 728 58
Promoter 4 R CTTTCTGCATCTCTACCCCTACTG 58
Exon 1 F TAAGGGGTTTTAAATCTACTTGAGCAT 664 60
Exon 1 R TGCAAACTCACTTTCAGTCCC 60
Exon 2 F TCACGGTGGTGTCTTTCTACC 661 62
Exon 2 R GCATTATCTACCTGAGGAAACACATA 62
Exon 3 F AATGTCATGCAATCAATGTAAAAAGT 639 57
Exon 3 R TCTAAGTGGAAAAAGTACTGGGGATA 57
Exon 4/5 F GAGGTAGCTTAACAACTAAATGGAGG 559 60
Exon 4/5 R TTGAGGAATGTCTTTCTGTCTATTTG 60
Exon 6 F AGATAATTGCAATGGTTTAGAAGTCC 430 58
Exon 6 R TAGTTTCAGCAAACCAAAACAAATAG 58
Exon 6 seq F TTTATTTAAGATTCTTTTCTTTTCTGTTG 261
Exon 6 seq R TTGGTATTTTCAGTTAGATTCTTTCTT
F; Forward primer, R; Reverse primer. For exon 6 an extra set of sequencing primers internal to the PCR amplicon of 430 bp was used.
doi:10.1371/journal.pone.0012993.t001
TNFSF13B/BAFF and Preeclampsia
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To predict possible functional relevance of the detected
TNFSF13B variants, we used different publicly available bioinfor-
matic tools for identifying transcription factor binding sites in
DNA sequences (http://www.gene-regulation.com), as well as
TransfacH Professional and MotifScanner. The programs use
different approaches to utilize the library of mononucleotide
weight matrices in the TRANSFACH [47] and Jaspar [48]
databases.
Electrophoretic Mobility Shift Assays (EMSA)
HeLa and T47D total nuclear protein extract was prepared and
stored as described [49]. Total protein was determined using the
Bio-Rad Protein Assay Reagent. The DNA oligonucleotides
(0.025 mmol) (Sigma-Aldrich) used to assay the three TNFSF13B
variants are presented in Table 2. All oligonucleotides were 59
end-labeled using T4 polynucleotide kinase (PNK) (New England
Biolabs) and [c33P] ATP (3000 Ci/mmol) (PerkinElmer) and
annealed to their complementary unlabeled oligonucleotides as
previously described [49]. The samples were purified according to
manufacturers’ instructions through G25 Microspin
TM columns
(GE Healthcare). The EMSA reactions were carried out in binding
buffer (4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM
DTT, 50 mM NaCl, 10 mM Tris–HCl (pH 7.5), 0.25 mg/ml
poly(dI-dC)) in a final volume of 10 ml. Nuclear extract (7 mg) was
incubated with double-stranded competitor oligonucleotides for
30 min at room temperature, followed by the addition of 50 fmol
of P33 labeled oligonucleotide and then incubated for another
30 min. Samples were mixed with 1 mlo f1 0 6 loading buffer
(250 mM Tris–HCl (pH 7.5), 0.1% bromophenol blue, 40%
glycerol) and run on a 4% polyacrylamide gel (37.5:1 acrylami-
de:bisacrylamide, 2.5% glycerol, 0.56 TBE) at 300 V. The gels
were fixed in 50% ethanol and 10% acetic acid for 1 h followed by
Phosphor Imager analysis (Bas-1800II) (Fujifilm) of the dried gel.
Replicated SNP Genotyping in the Norwegian Study
Population
DNA for genotypingwas extracted fromperipheral blood samples
stored in the HUNT biobank as described elsewhere [27,45].
Replicated SNP genotyping was performed at Southwest Founda-
tion for Biomedical Research, Texas, using TaqMan genotyping
assays (Applied Biosystems) on an Applied Biosystems’ 7900HT Fast
Real-Time PCR System. For each TaqMan SNP assay 50 ng of
genomic DNA was used in a 5 ml reaction volume with 2.5 ml
TaqMan Genotyping master mix, 0.125 ml TaqMan assay mix
(406) and 1.375 ml water. Four no template (water) controls were
incorporated into each 384-well plate. SNP genotype clustering and
individual sample genotype calls were interrogated using Applied
Biosystems’ Sequence Detection Systems software v2.2.2.
Statistical Methods
Genotype Error Checking. Genotypes pertaining to the
Aust/NZ study population not conforming to Mendelian
inheritance laws were identified and assessed using SimWalk2
[50]. Mendelian discrepancies and spurious recombinations were
removed by blanking those genotypes identified in SimWalk2 as
having a high probability of being in error. Norwegian genotypes
in this current study were compared to Norwegian genotypes in
our preliminary study using SNPlex technology which prioritized
the TNFSF13B gene [29].
SNP Allele Frequency Estimation. We used the statistical
genetics analysis program SOLAR [51] to estimate SNP allele
frequencies by using maximum likelihood techniques that account
for pedigree structure. Tests for deviations from Hardy-Weinberg
equilibrium (HWE) were also performed in SOLAR.
SNP Linkage Disequilibrium Estimates. Estimates of
pairwise linkage disequilibria parameters were used in a basic
correlation method to assess all disequilibria jointly in SOLAR. In
this approach, SNP genotypes are scored as -1, 0 and 1 (for the
AA, AB and BB genotypes, respectively) and the correlations
among these data vectors are calculated to give an unbiased
estimate of the squared LD correlation, rho (r).
SNP Association Analysis. Power calculations and SNP
association analyses were performed in SOLAR [51]. SNP
association analyses were conducted using SOLAR’s QTLD
procedure [52]. This procedure performs a test for population
stratification and two commonly used association tests: the
quantitative transmission disequilibrium test (QTDT) [53], and
the measured genotype test [54]. The QTDT procedure is not
limited to the scoring of allele transmission from parents to offspring
but extends further to assess the entire pedigree structure. The
scoring of allele transmission can be performed for quantitative or
Table 2. Oligonucleotides used for Electrophoretic mobility shift assays.
SNP Allele F/R* Sequence
rs16972197 G F 59-GCTTTCCCTTGACTGTGCCAATCC-39
GR 5 9-GGATTGGCACAGTCAAGGGAAAGC-39
CF 5 9-GCTTTCCCTTCACTGTGCCAATCC-39
CR 5 9-GGATTGGCACAGTGAAGGGAAAGC-39
rs16972194 G F 59-AAACTTCTTACTTAAGACTGTGTGGAAATGTAGAGT-39
GR 5 9-ACTCTACATTTCCACACAGTCTTAAGTAAGAAGTTT-39
AF 5 9-AAACTTCTTACTTAAGACTGTATGGAAATGTAGAGT-39
AR 5 9-ACTCTACATTTCCATACAGTCTTAAGTAAGAAGTTT-39
rs56124946 C F 59-GCTGCCTCTCCCTCGCCTCAGCTGTCTTT-39
CR 5 9-AAAGACAGCTGAGGCGAGGGAGAGGCAGC-39
GF 5 9-GCTGCCTCTCCCTGGCCTCAGCTGTCTTT-39
GR 5 9-AAAGACAGCTGAGGCCAGGGAGAGGCAGC-39
*orientation of oligo: Forward (F)/Reverse (R) strand.
doi:10.1371/journal.pone.0012993.t002
TNFSF13B/BAFF and Preeclampsia
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discretetraits using a threshold model [55]. The measured genotype
testusesastandardthresholdmodelassuminganunderlyingnormal
distributionof liability. Thethreshold model anditsassumptions are
near identical to those used in standard logistic regression but
benefits from the ease of interpretation with regard to genetic
effects. The measured genotype test of association can assess the
extent of genotypic mean differences (or the liability or risk scale)
between case and control singletons assuming a model of additive
geneaction[54].Duetothenon-familialstructureoftheNorwegian
study population, we can only present the measured genotype test
statistic for this cohort.
Multiple Hypothesis Testing. To accommodate for
multiple hypothesis testing, we used the approach of Moskvina
and Schmidt [56] to determine the effective number of
independent SNPs (i.e. tests) based on the pair-wise genotypic
correlations. This algorithmic approach has been implemented
into SOLAR and it evaluates the strength of correlation amongst
the observed genotypes at each SNP locus within a gene.
Results
Statistical Power analyses
We performed formal power calculations to assess the power to
detect an association (between a SNP and the dichotomous
preeclampsia phenotype – where affected are scored as 1 and
unaffected as 0) of a given relative size in the population. In the
Aust/NZ families, with a SNP-specific heritability of 0.01 to 0.05,
we predicted 80% power to identify functional effects that account
for as little as 3.5% of the total phenotypic variation with a
nominal alpha (significance) of 0.05. In the Norwegian case/
control cohort, we estimated an 80% likelihood of identifying a
SNP accounting for at least 2% of the total (dichotomous)
phenotypic variation.
TNFSF13B Gene Sequencing
The proximal promoter (2 kb upstream of the translation
start site), the 59UTR, 39UTR and all coding regions were
sequenced. In total, we identified nine SNPs (two novel, seven
known) and one known, single base insertion in the proximal
promoter or intronic sequence flanking the exons (Table 3 and
Figure 1).
TNFSF13B Genotyping and Association Analysis in the
Aust/NZ Families
The 74 Family Cohort (n=480) included 140 affected women
(20 with eclampsia, 120 with preeclampsia) and 146 unaffected
women (normotensive and non-proteinuric). At the time of custom
SNP pool design the single base insertion variant (rs33926705)
Figure 1. Schematic representation of the TNFSF13B gene and variants detected in a sub-set of founding or proband preeclamptic
women from the Aust/NZ study population. Solid blocks; untranslated exons, open blocks; translated exons.
doi:10.1371/journal.pone.0012993.g001
Table 3. TNFSF13B variants tested in the Aust/NZ and Norwegian study populations.
SNP Chr. Post. (bp)* Function Aust/NZ study population Norwegian study population
Allele (frequency) MGp QTDTp Allele (frequency) MGp
SNP_A-1967C 107718278 pp Failed genotyping assay Not tested
rs16972194 107718962 pp G (0.993) A (0.007) 0.380 0.015 G (0.997) A (0.003) 0.421
rs9514828 107719374 pp G (0.566) A (0.434) 0.406 0.915 Not tested
rs36206504 107719569 pp A (0.965) C (0.035) 0.714 0.162 Not tested
rs36206505 107719584 pp A (0.931) G (0.069) 0.125 0.618 Not tested
rs16972197 107719892 pp G (0.993) C (0.007) 0.380 0.015 G (0.997) C (0.003) 0.357
rs56124946 107720644 Intron 1 C (0.993) G (0.007) 0.380 0.015 C (0.991) G (0.009) 0.737
SNP_A17071G 107737282 Intron 3 Failed assay design Not tested
rs33926705 107757082
‘107757083 Intron 5 Not tested Not tested
rs61972017 107757114 Intron 5 A (0.988) C (0.012) 1.000 0.197 Not tested
Novel SNPs are denoted SNP_[UCSC reference template allele][bp position from TSS][alternative allele]. Alleles reported are orientated on the TOP strand (ftp://ftp.ncbi.
nih.gov/snp/database/Illumina_top_bot_strand.note.txt). * ref_assembly, human genome build 36.3, Abbreviations: TSS; translation start site, Chr.; chromosome, Post.;
position, bp; base pair, MGp; measured genotype test p-value, QTDTp; quantitative transmission disequilibrium test p-value, pp; proximal promoter.
doi:10.1371/journal.pone.0012993.t003
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(SNP_A17071G) failed assay design due to it residing within a
duplicate or repetitive region and the other novel SNP (SNP_A-
1967C) could not be successfully genotyped. The seven success-
fully typed SNPs in the Aust/NZ study population exhibited a
high sample genotype success rate ($98.5%) and all SNPs
conformed to Hardy-Weinberg expectations (p.0.05).
We observed association to preeclampsia (p=0. 0153) for
three rare SNPs (rs16972194, rs16972197 and rs56124946)
(Table 3). Based on the extent of linkage disequilibrium (LD)
between these SNPs (Figure 2) we were effectively testing five
independent SNPs in our association analyses. To correct for
multiple testing, these SNP correl a t i o n sr e t u r na na d j u s t e dp -
value threshold of 0.0102. Therefore, we present a borderline
association for three TNFSF13B SNPs (Figure 2) with preeclamp-
sia susceptibility in the Aust/NZ families with the QTDT statistic
(Table 3).
Bioinformatic Evaluation
Bioinformatic analysis of rs16972194, rs16972197 and
rs56124946 using MATCH
TM 1.0 [57] revealed that the rare
rs16972194 (A) allele created a promoter sequence with high core
similarity (core match; 0.948, matrix match; 0.932) to the binding
motif of transcription factor Oct-1. Oct-1 is a member of the POU
domain transcription factor family [58], and the DNA recognition
sequence is the octamer motif 59-ATGCAAT-39, which is shared
between several Oct/POU transcription factor family members
[59]. A more stringent bioinformatics analysis, examining whether
any other known transcription factor(s) could bind preferentially to
the minor allele, but not the major allele of rs16972194, was also
Figure 2. Linkage disequilibrium (LD) pattern for the successfully genotyped TNFSF13B SNPs in the Aust/NZ study population. LD is
measured by the squared value of the pair wise correlation (rho) amongst intra-genic genotypes and the strength of correlation is depicted in the
colored bar to the right of the LD plot. The intensity of red color increases with the strength of SNP allele correlation from white (0) indicating no
correlation (i.e. no LD) to red (1.0) indicating a perfect correlation (i.e. complete LD).
doi:10.1371/journal.pone.0012993.g002
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factors were collected from the TRANSFAC (version 2009.2)
and JASPAR CORE databases [48,60]. The Oct- motif was
confirmed, and additional shorter core sequences exhibiting a
preference to the rs16972194 minor (A) allele were identified. Of
these, the FOXC1 and YY1 transcription factor-motifs were the
most relevant.
Electrophoretic Mobility Shift Assays (EMSA)
We subsequently carried out electrophoretic mobility shift
assays (EMSA), using nuclear extracts from HeLa and T47D cells.
Radioactively labeled double stranded DNA oligonucleotide
probes representing the major and minor allele of each of the
three rare and associated SNPs were run with both nuclear
extracts to visualize binding of nuclear protein (Figure 3). All
probes demonstrated non-specific electrophoretic mobility shifts
(Figure 3). Unlabelled double stranded oligos for the wild type and
mutant alleles, as well as an unspecific competitor, were added in
separate reactions. The unspecific shifts were inhibited by these
competitors. Interestingly, the rs16972194 SNP demonstrated a
specific shift for the minor, but not the major, allele probe
(Figure 3). The minor allele unlabelled probe suppressed the shift
whereas the major allele unlabelled probe and the unspecific
competitor did not (Figure 3). This strongly suggests the creation of
a nuclear factor binding site by this variant. Antibodies for
transcription factors Oct1, Oct2, Oct3/4, Oct6, YY1 and FOXC1
were run in separate reactions, but no supershift was observed
under the current running conditions (result not shown).
Replicated TNFSF13B SNP Genotyping and Association
Analysis in the Norwegian Singletons
DNA samples were available for 851 confirmed cases of women
with preeclampsia and 1,440 women with a history of non-
preeclamptic pregnancies (controls). Of the available cases, 737
women were registered with one and 114 women with more than
one preeclamptic pregnancy. As expected, gestational age (273 d
vs. 282 d, p,0.001) and birth weight (3156 g vs. 3457 g, p,0.001)
differed between the neonates in preeclamptic and non-pre-
eclamptic pregnancies. Maternal age at first pregnancy was higher
in the case group (23.6 yrs vs. 22.8 yrs, p,0.001), but the groups
did not differ with respect to parity (2.56 vs. 2.55, p.0.05). After
adjusting for maternal age, the differences in clinical phenotype
between case and control groups remained significant (p,0.001).
All three rare SNPs associated to preeclampsia were successfully
genotyped in the Norwegian study population. A high genotyping
success rate ($97.1%) was observed and all three SNPs were in
Hardy-Weinberg equilibrium (p.0.05). Independent genotyping
of these SNPs did not replicate the results attained in the Aust/NZ
families (Table 3).
Discussion
The elucidation of genetic risk factors contributing to
preeclampsia susceptibility has become a priority of obstetric
research. It is well known that both maternal and paternal factors
influence the preeclampsia phenotype [9,11,13,14]. To identify
maternal genetic contributions to preeclampsia our positional
cloning approach identified a susceptibility QTL on chromosome
13q [20], and the TNFSF13B gene was prioritized as the most
promising candidate under this QTL [29]. In the current study, a
targeted molecular genetic evaluation of TNFSF13B was under-
taken. We report borderline association to a putative functional
SNP within the proximal promoter region of TNFSF13B with
preeclampsia susceptibility in affected Aust/NZ families. The
finding is not replicated in a Norwegian case/control population
cohort.
The early changes of pregnancy include a shift of the Th1/Th2
cytokine balance towards Th2 predominance [61]. Inflammatory/
infectious processes may alter this balance towards a Th1 profile
less favorable for pregnancy [61]. TNFSF13B is regulated by
inflammatory response cytokines [62–64] and stimulates macro-
phages to secrete proinflammatory cytokines, enhancing the
cascade [32]. Interference with the homeostatic regulation of
TNFSF13B could therefore potentially disturb the finely tuned
cytokine balance of pregnancy. Decidual stromal cells (DSCs) have
been shown to express TNFSF13B mRNA and protein [40] and
DSCs are involved in a number of different functions that are
important for the immunological cross-talk between mother and
fetus [65]. Our finding may therefore reflect an abnormal
immunological function of DSCs at the maternal-fetal interface.
The interaction between decidual natural killer (NK) cells and
the allogenic extravillous trophoblast (EVT) cells is suggested to
contribute to the depth of EVT cell invasion during implantation
and placentation [66,67]. NK-cells are the predominant leucocytes
found in decidua [67] and NK- cell activity is elevated by
TNFSF13B in mice [68,69]. In humans, TNFSF13B has been
shown to relay immunological response to toll-like receptor (TLR)
3 and 4 binding [70,71]. TLRs are expressed on placental NK
cells. They help discriminate between ‘‘self’’ and ‘‘non-self’’, and
have been shown to recognize infectious agents as well as
endogenous danger signals [61,72]. These biological functions
are implicated in preeclampsia pathogenesis [5,10,73], and TLRs
have been assigned a role in pregnancy-associated complications
such as intrauterine growth restriction, pre-term delivery and
preeclampsia [74]. It is therefore tempting to speculate, that
disturbed TLR signaling might be one mechanism by which
aberrant TNFSF13B regulation could confer susceptibility to
preeclampsia.
We observe differential nuclear binding to the minor allele of
the TNFSF13B promoter area rs16972194 SNP, thus suggesting it
as a putative functional, albeit rare, variant. A recent report
showed that SNPs contribute substantially to genetic variation
leading to aberrant transcription factor binding, and that this
might be an important evolutionary mechanism [75]. Transcrip-
tional regulation is proving to be highly complex, as illustrated by
the FANTOM consortiums attempt to describe the transcriptional
landscape of the mouse genome [76]. In the human genome, over
2,500 proteins with DNA binding motifs are predicted, and it is
estimated that about 8% of human proteins are transcription
factors [77]. Of these, only about 10% are well characterized and
included in available databases for motif searches [48,60]. HeLa
cells are widely used as a model system for biomedical research on
both normal and disease molecular processes [78]. A wide variety
of nuclear factors are expressed in this cell type, including
transcription factors only expressed in embryonic stem-cells and
not in differentiated tissues [79]. Our EMSA results show
differential binding of a nuclear factor to the sequence in question.
The finding was replicated using T47 cells. However, further
investigation of the protein band representing nuclear factor
binding to the rs16972194 minor allele and in vivo confirmation of
the result is warranted. The role of the identified putative
functional variant in other TNFSF13B related diseases should
also be subject of further investigation.
The Aust/NZ sequencing sample set ensures a high probability
of detecting common frequency variants within the population.
However, our choice of affected women who are either pedigree
founders or probands for re-sequencing will also increase the
likelihood of identifying rare functional variants that are enriched
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number of genome wide association studies have been undertaken
for numerous common complex diseases, assuming that common
disease is caused by common variation (the common disease-
common variant (CDCV) hypothesis) [80]. This approach has
provided new insight [81], but a notable knowledge ‘‘gap’’ of 90–
95% of the genetic liability to these diseases is left unaccounted for
[80]. As shown for extensively studied disease genes, such as
BRCA1 and BRCA2, rare variants might be population specific, but
yield a higher individual risk of disease than common variants (the
common disease rare-variant (CDRV) hypothesis) [82,83]. There-
fore, most geneticists appreciate that the CDCV and CDRV
hypotheses both have their place in the understanding of
heterogeneous genetic disorders. The rare TNFSF13B variants
exhibiting borderline association with preeclampsia susceptibility
in the Aust/NZ families were not replicated in the Norwegian
population sample. Confirming the biological importance of rare
predisposing variants between populations is a challenge [80], and
further genetic and molecular investigation in other populations is
required.
The Norwegian population cohort has a larger sample size than
the Aust/NZ family cohort. However, the power of a study is also
influenced by the stringency of the diagnosis and the pedigree
information included in the statistical analyses. In both the Aust/
NZ and Norwegian study populations, the preeclampsia diagnosis
was based on the development of new onset hypertension and
proteinuria during pregnancy. However, preeclampsia is a
complex disease, and preeclamptic cases selected from a
population sample represent a more heterogeneous group, than
a collection of family samples. The MBRN did not include
absolute values of blood pressure and proteinuria, and severity of
preeclampsia was not reported to the registry before 1998. Thus,
we are not able to include this information in our analyses.
However, women with a familial disposition generally display
more severe manifestations of the disease [84], and this may have
influenced our results. The available information about relatedness
in the Aust/NZ pedigree sample set allows a wider range of
potential test statistics to be considered. Hence, we applied both
the measured genotype association test and the QTDT which
controls for any potential latent stratification in the data. In the
absence of hidden stratification and residual linkage effects, the
measured genotype test is asymptotically more powerful than the
QTDT [85]. However, in the presence of certain types of latent
stratification, the QTDT can be more powerful. Similarly, residual
linkage (reflective of additional functional variants near the
associated marker) can also lead to a more powerful QTDT.
Such additional potential genetic signals have no influence in the
analysis of unrelated individuals. Thus, even though the sample
size of the Norwegian cohort is larger its composition of solely
unrelated females may have rendered it somewhat less powerful
for detecting the observed effect if such complexities are involved.
In conclusion, we observe borderline association between three
rare TNFSF13B SNPs, one of which exhibits putative functional
characteristics, and maternal preeclampsia genetic susceptibility in
our Aust/NZ families. Our observation supports TNFSF13B as a
potential preeclampsia susceptibility gene in a region of known
genetic linkage, and adds evidence to its importance for a
successful human pregnancy. Furthermore, showing differential
nuclear factor binding to the minor allele of rs16972194, we
propose this variant as a candidate for additional functional
evaluation.
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